Blockade of IL-23: What is in the Pipeline?

J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72.doi: 10.1093/ecco-jcc/jjab185.


Tommaso Lorenzo Parigi 1 2Marietta Iacucci 1Subrata Ghosh 3


Author information

1Institute of Immunology and Immunotherapy NIHR Birmingham Biomedical Research Centre, University Hospitals NHS Foundation Trust and University of Birmingham, Birmingham, UK.

2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

3APC Microbiome Ireland Centre, College of Medicine and Health, University College Cork, Ireland.


Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.



© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.